CHMP selects drugs for EU market approvalEMAs human medicines committee (CHMP) recommended seven medicines for approval at its October 2019 meeting. more ➔
New risk factor for autism and epilepsy id...A molecular transporter is critical for the proper maturation of neurons underlying neurodevelopmental disorders. more ➔
Healx Ltd raises $56m in Series B financin...AI-driven drug repurposing company Healx Ltd (Cambridge, UK) raises US$56m in a Series B financing and launches global accelerator programme for orphan diseases. more ➔
4SC expands domatinostat combo testingThe Netherlands Cancer Institute (NKI) has joined 4SC AG as a partner in conducting a multicentre study of dominatostat/checkpoint blocker combos in treatment-naive melanoma patients. more ➔
Cell transdifferentiation specialist Mogri... British start-up company Mogrify Ltd (Cambridge, UK) has added US$16m from a Series A round to its US$3.7m seed financing in February 2019. Existing investor Ahren Innovation Capital led the round, … more ➔
Patient’s organoids predict response... A new test based on tumour organoids can predict how patients with advanced colorectal cancer respond to chemotherapy treatment. more ➔
ADC Therapeutics enters licence option dea...ADC Therapeutics SA has entered a R&D pact with Affimer developer Avacta Group plc aimed at creating and licencing Affimer drug conjugates. more ➔
Novo Nordisk enters haemophilia gene thera...Licencing bluebird bios Inc know-how and technology in one-time gene therapies, Novo Nordisk A/S tries to get a foothold in the emerging haemophilia A gene therapy market. more ➔
Evotec and Celmatix enter strategic partne... Evotec SE has expanded its drug discovery customer base with US women’s health specialist Celmatix Inc. more ➔
Qiagen/Illumina: Earthquake in NGS IVD mar...QIAGEN and Illumina join forces in the next-gen sequencing-based IVD testing and companion diagnostics market announcing a 15-year collaboration. more ➔
